What Happened?
Redwood City, CA-based Adverum Appointed Rupert D`Souza as Chief Financial Officer
About the Company
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. Adverum is evaluating its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration.
About the Person
Rupert D`Souza is Chief Financial Officer at Adverum. Previously, Rupert held various senior HR leadership roles in the industry.
Info Source
News
Short Profile